Pharma BD Deal Intelligence

Gilead Sciences Inc. / Kite Pharma Inc.

2017 · Acquisition/Merger · $11.9B · Complete

Announcement Sentiment

Neutral / mixed

Outcome Score

Largely worked — most objectives met.

Gilead Sciences acquired Kite Pharma for approximately $11.9 billion ($180.00 per share in cash), establishing Gilead as a leader in CAR-T cell therapy with axicabtagene ciloleucel (later approved as Yescarta) for aggressive non-Hodgkin lymphoma.

Key facts

Announced Aug 28, 2017
Closed Oct 03, 2017
Deal value $11.9B
Deal type Acquisition/Merger
Therapeutic area Hematology, Oncology
Indications Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Primary Mediastinal B-Cell Lymphoma, Mantle Cell Lymphoma
Key assets axicabtagene ciloleucel (KTE-C19/Yescarta), KTE-585 (anti-BCMA CAR-T), KITE-718 (MAGE A3/A6 TCR), CAR-T manufacturing platform
Mechanism Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals